QPS

QPS expands phase I clinic in the Netherlands

Tuesday, November 27, 2012 11:31 AM

QPS Holdings has completed a 24-bed annex to its phase I clinic at the University Medical Center Groningen in the Netherlands, bringing to 58 its bed capacity for the conduct of first-in-man and early-phase research on novel and complex therapeutic agents.

More... »

QPS acquires JSW Life Sciences

Wednesday, August 29, 2012 09:47 AM

QPS, a global full-service GLP/GCP-compliant CRO based in Newark, Del., has acquired a majority interest in JSW Life Sciences, a provider of preclinical and clinical phase II-IV drug development services. The company will be known as QPS JSW.

More... »

CRO QPS acquires Qualitix

Wednesday, March 9, 2011 01:28 PM

QPS, a global GLP/GCP-compliant CRO providing testing services for preclinical and clinical R&D, has acquired a majority interest of Qualitix Clinical Research. Qualitix, a spin-off of Taiwan-based biotech Genovate, is a CRO and site management organization (SMO) with offices in Taiwan and China. Genovate will retain a minority interest in Qualitix, which will be known as QPS-Qualitix Taiwan.

More... »

QPS completes acquisition of Xendo

Friday, July 30, 2010 08:14 AM

QPS Holdings, a CRO providing testing services to support preclinical and clinical research and development, announced the completion of its acquisition of Xendo Drug Development (XDD), headquartered in Groningen, The Netherlands.

More... »

ICON, QPS Receive Industry Accreditations

Friday, September 18, 2009 07:14 AM

Dublin, Ireland-based contract research organization (CRO) ICON received industry accreditations for three of its laboratories in the UK and Singapore, and Newark, Del.-based QPS received a Good Laboratory Practice (GLP) certificate for its Taiwan operations.

More... »

QPS Bolsters New Translational Medicine Group

Wednesday, August 6, 2008 07:28 AM

Newark, Del.-based QPS, a provider of research services for the pharmaceutical industry, named Dr. LingSing K. Chen to head its new Translational Medicine department.

“In its Critical Path Initiative, the FDA identified—correctly, we believe—the need for this country to make significant improvements to the process under which new drugs are developed,” said Dr. Ben Chien, QPS president and chief executive officer. “By adding a department of Translational Medicine, we hope to play an integral role in the process of moving research discoveries from the laboratory into clinical practice more rapidly.”

Translational medicine is a scientific discipline that refers to the translation of basic research into new therapies for patients.

“The remarkable growth in our biomarkers business areas led us to consider this path,” Dr. Chien said. “QPS considers the creation of a Translational Medicine department pivotal to providing new technologies to support preclinical and clinical drug development worldwide.”

Chien noted that many QPS clients have already formed Translational Medicine units to facilitate the interaction between basic research and clinical medicine, particularly in clinical trials.

Chien said QPS would combine two existing groups, Immunobiomarker and Molecular Biology, to form the new department. Dr. LingSing K. Chen, former executive director of the Molecular Biology group, will head QPS’ new Translational Medicine department.

“Dr. Chen is a founding member of our Molecular Biology group and has established very diverse capabilities within a short period of time,” Chien said. “She is a determined leader with a great deal of entrepreneurial spirit and I have every reason to believe in the success of our new venture.”

Prior to joining QPS, Chen held executive positions at Wyeth Pharmaceuticals and as a senior advisor to the Industrial Technology Research Institute (ITRI) in Taiwan.

More... »